Tags

Type your tag names separated by a space and hit enter

Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature.
Medicine (Baltimore). 2020 May 22; 99(21):e20390.M

Abstract

RATIONALE

Fibrates are widely used to control hypertriglyceridemia and mixed dyslipidemia alone or in combination with statins. These drugs have rare, but severe and potentially vital adverse reactions of rhabdomyolysis and secondary acute renal failure (ARF). The objective of this article is to analyze this adverse effect of fibrates and ensure the safety of drug use.

PATIENT CONCERNS

We report a case of rhabdomyolysis and ARF due to fenofibrate monotherapy in a 68-year-old female with post-pancreatitis diabetes mellitus and review reported cases of rhabdomyolysis correlated with fibrates monotherapy.

DIAGNOSIS

The patient was diagnosed with rhabdomyolysis associated with fenofibrate monotherapy as confirmed by symptoms of fatigue and muscle pain, and elevated levels of myoglobin and creatine kinase.

INTERVENTIONS

Fenofibrate therapy was discontinued. Moreover, intravenous fluids, urinary alkalization, and diuretic were performed.

OUTCOMES

The symptoms were completely relieved, and relevant laboratory indexes returned to normal range during follow-up.

LESSONS

Physicians should be aware of the side effect of rhabdomyolysis of fibrates, and patients should also be informed about this potential side effect, especially for patients with high-risk factors. A favorable outcome can be achieved by timely diagnosis and prompt treatment.

Authors+Show Affiliations

Department of Endocrinology of Lu'an Second People's Hospital, The Affiliated Hospital of West Anhui Health Vocational College.Department of Endocrinology of Lu'an Second People's Hospital, The Affiliated Hospital of West Anhui Health Vocational College.Department of Hematology of Lu'an People's Hospital, The Lu'an Affiliated Hospital of Anhui Medical University, Lu'an, Anhui, China.

Pub Type(s)

Case Reports
Journal Article

Language

eng

PubMed ID

32481339

Citation

Zhou, Jingjing, et al. "Fenofibrate Monotherapy-induced Rhabdomyolysis in a Patient With Post-pancreatitis Diabetes Mellitus: a Rare Case Report and a Review of the Literature." Medicine, vol. 99, no. 21, 2020, pp. e20390.
Zhou J, Li D, Cheng Q. Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature. Medicine (Baltimore). 2020;99(21):e20390.
Zhou, J., Li, D., & Cheng, Q. (2020). Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature. Medicine, 99(21), e20390. https://doi.org/10.1097/MD.0000000000020390
Zhou J, Li D, Cheng Q. Fenofibrate Monotherapy-induced Rhabdomyolysis in a Patient With Post-pancreatitis Diabetes Mellitus: a Rare Case Report and a Review of the Literature. Medicine (Baltimore). 2020 May 22;99(21):e20390. PubMed PMID: 32481339.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Fenofibrate monotherapy-induced rhabdomyolysis in a patient with post-pancreatitis diabetes mellitus: A rare case report and a review of the literature. AU - Zhou,Jingjing, AU - Li,Dongfeng, AU - Cheng,Qiansong, PY - 2020/6/3/entrez PY - 2020/6/3/pubmed PY - 2020/6/17/medline SP - e20390 EP - e20390 JF - Medicine JO - Medicine (Baltimore) VL - 99 IS - 21 N2 - RATIONALE: Fibrates are widely used to control hypertriglyceridemia and mixed dyslipidemia alone or in combination with statins. These drugs have rare, but severe and potentially vital adverse reactions of rhabdomyolysis and secondary acute renal failure (ARF). The objective of this article is to analyze this adverse effect of fibrates and ensure the safety of drug use. PATIENT CONCERNS: We report a case of rhabdomyolysis and ARF due to fenofibrate monotherapy in a 68-year-old female with post-pancreatitis diabetes mellitus and review reported cases of rhabdomyolysis correlated with fibrates monotherapy. DIAGNOSIS: The patient was diagnosed with rhabdomyolysis associated with fenofibrate monotherapy as confirmed by symptoms of fatigue and muscle pain, and elevated levels of myoglobin and creatine kinase. INTERVENTIONS: Fenofibrate therapy was discontinued. Moreover, intravenous fluids, urinary alkalization, and diuretic were performed. OUTCOMES: The symptoms were completely relieved, and relevant laboratory indexes returned to normal range during follow-up. LESSONS: Physicians should be aware of the side effect of rhabdomyolysis of fibrates, and patients should also be informed about this potential side effect, especially for patients with high-risk factors. A favorable outcome can be achieved by timely diagnosis and prompt treatment. SN - 1536-5964 UR - https://www.unboundmedicine.com/medline/citation/32481339/Fenofibrate_monotherapy-induced_rhabdomyolysis_in_a_patient_with_post-pancreatitis_diabetes_mellitus:_A_rare_case_report_and_a_review_of_the_literature L2 - https://doi.org/10.1097/MD.0000000000020390 DB - PRIME DP - Unbound Medicine ER -